<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515719</url>
  </required_header>
  <id_info>
    <org_study_id>Btrial</org_study_id>
    <nct_id>NCT04515719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Belimumab in SLE Patients</brief_title>
  <official_title>Efficacy and Safety of Belimumab for Prevention of Disease Flares in SLE Patients With Low Disease Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic inflammatory systemic autoimmune disease.&#xD;
      Recurrent relapses of disease and development of long-term organ damage are two key unsolved&#xD;
      clinical problems. Belimumab is the only FDA-approved biological agent for SLE. Data showed&#xD;
      that treatment with belimumab on the background of standard therapy was effective in active&#xD;
      SLE patients. However, the efficacy of low-dose belimumab for prevention of disease flares in&#xD;
      SLE patients with low disease activity is to be explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with the&#xD;
      incidence of about 70/100,000 in China. Recurrent relapses of disease and development of&#xD;
      long-term organ damage are two key unsolved clinical problems. Its pathogenesis is still&#xD;
      unclear, but B cells have been confirmed to play a vital role in it. Belimumab, a&#xD;
      B-lymphocyte stimulating factor (Blys) inhibitor, was the only FDA-approved biological agent&#xD;
      for SLE. BLISS-52 showed that more active lupus patients had their SELENA-SLEDAI score&#xD;
      reduced by at least 4 points during 52 weeks with belimumab 10 mg/kg (58% vs 46%, p=0·0024)&#xD;
      than with placebo. But there was limited data about belimumab in SLE patients with low&#xD;
      disease activity. Our previous study indicated that even these patients still have an annual&#xD;
      flare rate of 30-40%. Therefore, we try to explore whether low-dose of belimumab could&#xD;
      prevent the disease flares in SLE patients with low disease activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with disease flares</measure>
    <time_frame>52 weeks</time_frame>
    <description>Disease flare is defined by modified SELENA-SLEDAI SLE flare index (SFI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with mild/moderate flares</measure>
    <time_frame>52 weeks</time_frame>
    <description>Disease flare is defined by modified SELENA-SLEDAI SLE flare index (SFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with major flares</measure>
    <time_frame>52 weeks</time_frame>
    <description>Disease flare is defined by modified SELENA-SLEDAI SLE flare index (SFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first disease flare</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prednisone dose at each visit</measure>
    <time_frame>52 weeks</time_frame>
    <description>compare the prednisone dose at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SELENA-SLEDAI score at each visit</measure>
    <time_frame>52 weeks</time_frame>
    <description>compare the disease activity measured by SELENA-SLEDAI score at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BiLAG score at each visit</measure>
    <time_frame>52 weeks</time_frame>
    <description>compare the disease activity measured by BILAG score at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>the safety of belimumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Belimumab 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Belimumab</intervention_name>
    <description>Belimumab 2mg/kg intravenously</description>
    <arm_group_label>Belimumab 2mg/kg</arm_group_label>
    <other_name>BENLYSTA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years;&#xD;
&#xD;
          2. Patients with low disease activity (score≤ 6 at screening on SLEDAI); no British Isles&#xD;
             Lupus Assessment Group (BILAG) A and no more than one B;&#xD;
&#xD;
          3. A stable treatment regimen with fixed doses of prednisone (≤ 20mg/day), antimalarial,&#xD;
             or immunosuppressive drugs (azathioprine/mycophenolate mofetil/&#xD;
             methotrexate/ciclosporin/leflunomide/tacrolimus) for at least 30 days.&#xD;
&#xD;
          4. Sign the informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) &gt; 2 times upper&#xD;
             normal limits;&#xD;
&#xD;
          2. Creatinine clearance rate &lt; 60ml/min;&#xD;
&#xD;
          3. Exposure to cyclophosphamide within past 6 months before screening;&#xD;
&#xD;
          4. Exposure to any B cell targeted therapy (Rituximab/belimumab) within past 1 year&#xD;
             before screening;&#xD;
&#xD;
          5. History of Malignancy;&#xD;
&#xD;
          6. History of herpes zoster with past 3 months before screening.&#xD;
&#xD;
          7. Chronic HBV/HCV hepatitis；&#xD;
&#xD;
          8. Current infections (HIV/tuberculosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fangfang Sun</last_name>
    <phone>86-021-34506393</phone>
    <email>fiona_rj@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shuang Ye, MD</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Ye, MD</last_name>
      <phone>+8613817615871</phone>
      <email>ye_shuang2000@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Huijing Wang, postgraduate</last_name>
      <phone>+8618267851823</phone>
      <email>whj30813@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.</citation>
    <PMID>21296403</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Belimumab</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Disease flare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

